Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)

Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)

US Patent 10906975 · Granted Feb 2, 2021

Estimated economic value: $45,487,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity2024
Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity2024
Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Nucleic acids encoding antibodies that bind and block triggering receptor expres2024
Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcuta2023
Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity2021